Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Legend Biotech Corp ADR
(NQ:
LEGN
)
57.50
+0.12 (+0.21%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Legend Biotech Corp ADR
< Previous
1
2
3
4
5
6
7
8
9
Next >
Week In Review: Legend Partners DLL3 CAR-T Candidate With Novartis In $1.2 Billion Deal
November 18, 2023
Legend Biotech partnered its DLL3 CAR-T candidates to Novartis in a $1.2 billion agreement, with $100 million offered upfront. Novartis will own worldwide rights to develop, manufacture, and...
Via
Talk Markets
Looking for Stocks to Buy? Here Are the Companies Johnson & Johnson Is Betting the Most On
November 16, 2023
Unsurprisingly, Johnson & Johnson's top investments are all in the healthcare sector.
Via
The Motley Fool
Legend Biotech Announces Exclusive, Global License Agreement for Certain CAR-T Therapies Targeting DLL3
November 13, 2023
From
Legend Biotech Corporation
Via
Business Wire
Legend Biotech to Host Investor Conference Call on Third-Quarter Results
November 07, 2023
From
Legend Biotech Corporation
Via
Business Wire
Analyst Ratings for Legend Biotech
October 18, 2023
Via
Benzinga
The Latest Analyst Ratings for Legend Biotech
August 16, 2023
Via
Benzinga
Legend Biotech to Showcase Leadership in Multiple Myeloma Treatment at the ASH 2023 Annual Meeting
November 02, 2023
From
Legend Biotech Corporation
Via
Business Wire
Positive Outlook On Johnson & Johnson's Partner Legend Biotech: Analyst Confident On Blood Cancer Drug
October 18, 2023
Legend Biotech Corporation's (NASDAQ: LEGN) partner, Johnson & Johnson (NYSE: JNJ), reported Q3 Carvykti revenues of $152 million,
Via
Benzinga
Legend Biotech Reports Second Quarter 2023 Results and Recent Highlights
August 15, 2023
From
Legend Biotech Corporation
Via
Business Wire
3 Biotech Stocks That Analysts Are Drooling Over
August 07, 2023
With the medical science realm representing one of the most complex markets, these top analyst biotech picks can be worth your time.
Via
InvestorPlace
The Latest Analyst Ratings for Legend Biotech
July 20, 2023
Via
Benzinga
The Latest Analyst Ratings for Legend Biotech
June 13, 2023
Via
Benzinga
Legend Biotech's Breakthrough in Multiple Myeloma Study Prompts Positive Analyst Forecast
June 06, 2023
Via
Benzinga
Legend Biotech to Host Investor Conference Call on Second-Quarter Results
August 03, 2023
From
Legend Biotech Corporation
Via
Business Wire
Arcellx, A Top 5% Biotech, Dives After A 'Perfect Storm' Leads To A Patient's Death
June 20, 2023
A patient died in Arcellx's multiple myeloma drug study. But the underlying factors are complex.
Via
Investor's Business Daily
Week In Review: Shanghai HighTide Therapeutics Files For Hong Kong IPO
June 10, 2023
HighTide Therapeutics filed for an IPO on the Hong Kong Exchange. Additionally, Shanghai Fosun Pharma will partner with the International Finance Corp to build a pharmaceutical production facility and...
Via
Talk Markets
Legend Biotech Announces Submission of Supplemental Application to the U.S. FDA for Expanded Use of CARVYKTI® (ciltacabtagene autoleucel)
June 06, 2023
From
Legend Biotech Corporation
Via
Business Wire
Expert Ratings for Legend Biotech
May 25, 2023
Via
Benzinga
Analyst's Verdict on Legend Biotech: Doubts On Commercial Execution, Long- Term Market Share
May 25, 2023
Via
Benzinga
Ciltacabtagene Autoleucel (cilta-cel) Reduced Risk of Disease Progression or Death by 74% vs Standard Regimens for Adult Patients with Relapsed and Refractory Multiple Myeloma in CARTITUDE-4 Study
June 05, 2023
From
Legend Biotech
Via
Business Wire
Legend Biotech Announces Participation in Upcoming Investor Conferences
June 02, 2023
From
Legend Biotech
Via
Business Wire
Promising Developments Announced Ahead of 2023 ASCO Annual Meeting’s Oral Presentations
May 26, 2023
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:GILD),(NASDAQ:IMGN),(NASDAQ:DAWN),(NASDAQ:LEGN) EQNX::TICKER_END
Via
FinancialNewsMedia
Exposures
Product Safety
Benzinga's Top Ratings Upgrades, Downgrades For May 25, 2023
May 25, 2023
Via
Benzinga
Legend Biotech Announces Submission to the European Medicines Agency for Expanded Use of CARVYKTI® (ciltacabtagene autoleucel)
May 25, 2023
From
Legend Biotech Corporation
Via
Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For May 22, 2023
May 22, 2023
Via
Benzinga
Legend Biotech Reports First Quarter 2023 Results and Recent Highlights
May 18, 2023
From
Legend Biotech Corporation
Via
Business Wire
Legend Biotech to Demonstrate Progress in Advancing Potential Treatment Options for Patients with Multiple Myeloma at ASCO and EHA Annual Meetings
May 16, 2023
From
Legend Biotech Corporation
Via
Business Wire
Legend Biotech Announces Participation in Upcoming Investor Conference
May 11, 2023
From
Legend Biotech Corporation
Via
Business Wire
10 Health Care Stocks With Whale Alerts In Today's Session
May 10, 2023
Via
Benzinga
Legend Biotech Corporation Announces Pricing of Registered Direct Offering of $350 Million of American Depositary Shares
May 08, 2023
From
Legend Biotech Corporation
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.